Hepatorenal Syndrome MCQ Quiz | Hepatology & Biliary

Welcome to the Hepatorenal Syndrome (HRS) MCQ Quiz, specifically designed for MBBS students navigating the complexities of Hepatology. This quiz covers the core concepts of HRS, a life-threatening complication of advanced liver disease. You will be tested on its pathophysiology, diagnostic criteria, clinical types, and modern management strategies, including pharmacological interventions and definitive treatments. This assessment consists of 25 multiple-choice questions to help you solidify your understanding and prepare for your examinations. After submitting your answers, you will receive your score and see a detailed breakdown of correct and incorrect responses. You can also download a PDF copy of all questions with their correct answers for future revision. Good luck!

1. What is the primary pathophysiological hallmark of Hepatorenal Syndrome (HRS)?

2. Which of the following is a common precipitating factor for HRS in a patient with cirrhosis?

3. What is the key differentiating feature between HRS-AKI (formerly Type 1) and HRS-NAKI (formerly Type 2)?

4. Splanchnic vasodilation in cirrhosis leads to what immediate compensatory response to maintain blood pressure?

5. Which of the following is a major criterion for the diagnosis of HRS?

6. The absence of which condition is crucial for diagnosing HRS?

7. A typical urine finding in a patient with HRS is:

9. Why is albumin co-administered with vasoconstrictors in HRS treatment?

10. What is considered the definitive treatment for Hepatorenal Syndrome?

11. How does terlipressin work to improve renal function in HRS?

12. Which urinary finding is more indicative of Acute Tubular Necrosis (ATN) rather than HRS?

13. According to the International Club of Ascites (ICA) criteria, diagnosis of AKI in patients with cirrhosis requires an increase in serum creatinine of at least:

14. Which intervention is proven to reduce the incidence of HRS in patients with Spontaneous Bacterial Peritonitis (SBP)?

15. What is the mechanism of action of midodrine, used in the treatment of HRS?

16. Octreotide, often used with midodrine, acts by:

17. When might Transjugular Intrahepatic Portosystemic Shunt (TIPS) be considered for HRS?

18. What is the median survival for untreated HRS-AKI (Type 1)?

19. In the pathophysiology of HRS, the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system are:

20. A characteristic finding in HRS is a urine sodium concentration of:

21. Before diagnosing HRS, a patient must show no sustained improvement in renal function after at least 2 days of:

22. The new nomenclature for HRS includes HRS-AKI (formerly Type 1) and HRS-NAKI. What does NAKI stand for?

23. In the context of infection like SBP, how do Pathogen-Associated Molecular Patterns (PAMPs) contribute to HRS pathophysiology?

24. What cardiovascular finding is typically associated with the hyperdynamic circulation of advanced cirrhosis that precedes HRS?

25. Which of the following is a major contraindication for terlipressin therapy?